Cytokinetics, Inc. (CYTK) Posts Q4 Loss of 16c/Share; Guides FY12 Revs
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q4 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $757 thousand versus the consensus estimate of $5.62 million.
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.